We are live on ! Find out more
ALT icon

Altimmune

173 hedge funds and large institutions have $282M invested in Altimmune in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $8.07M

13% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 47

13% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 40

1% more funds holding

Funds holding: 172173 (+1)

22.96% less ownership

Funds ownership: 82.78%59.83% (-23%)

38% less capital invested

Capital invested by funds: $453M → $282M (-$171M)

75% less funds holding in top 10

Funds holding in top 10: 41 (-3)

Holders
173
Holders Change
+1
Holders Change %
+0.58%
% of All Funds
2.5%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.01%
New
45
Increased
53
Reduced
47
Closed
40
Calls
$12.4M
Puts
$8.07M
Net Calls
+$4.35M
Net Calls Change
-$4.63M

ALT Hedge Fund Activity: Q2 2024 in Review

173 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2024, worth a combined $282M — down 38% from $453M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new ALT positions and 40 closed out — a net gain of 5 holders — while 53 added to existing stakes and 47 trimmed.

The largest buyer was Vanguard Group, adding an estimated $13.1M. The largest seller was State Street, cutting an estimated $35M.

  • 173 institutional investors held Altimmune (ALT) as of Q2 2024, up from 172 in Q1 2024.
  • Funds reported $282M of Altimmune stock for Q2 2024, down 38% quarter-over-quarter.
  • 45 funds opened new Altimmune positions in Q2 2024 and 40 closed out, a net change of +5 holders.
  • The largest Altimmune buyer in Q2 2024 was Vanguard Group, an estimated $13.1M added.
  • The largest Altimmune seller in Q2 2024 was State Street, an estimated $35M sold.

Based on aggregated 13F filings for Q2 2024.